Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-1.23% $7.25
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 198.32 mill |
EPS: | -2.53 |
P/E: | -2.87 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 27.36 mill |
Avg Daily Volume: | 0.344 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.87 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.49x |
Company: PE -2.87 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.705 (-109.73%) $-7.96 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 6.63 - 7.87 ( +/- 8.61%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Vazzano Joseph Walter | Sell | 703 | Common stock |
2024-03-04 | O'malley Brendan M. | Sell | 183 | Common stock |
2024-02-06 | Seshadri Vishwas | Buy | 20 000 | Common Stock |
2024-01-17 | Alvino Mark | Sell | 7 084 | Common Stock |
2023-10-16 | Seshadri Vishwas | Sell | 181 | Common Stock |
INSIDER POWER |
---|
81.17 |
Last 95 transactions |
Buy: 4 747 231 | Sell: 745 827 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.25 (-1.23% ) |
Volume | 0.267 mill |
Avg. Vol. | 0.344 mill |
% of Avg. Vol | 77.71 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:30 | buy | $5.34 | N/A | Active |
---|
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.